tbuckley/cabot-search huggingface dataset:
Acanthamoeba Keratitis
Authors: Lanxing Fu, Ahmed Gomaa
Journal: New England Journal of Medicine (2019)

A 41-year-old woman who wore soft contact lenses presented with pain, blurry vision, and sensitivity to light in her left eye. Cultures of corneal scrapings grew Acanthamoeba polyphaga, and a diagnosis of acanthamoeba keratitis was made.
The effect of statin therapy on ventricular late potentials in patients with acute myocardial infarction receiving thrombolytic therapy Meral Kayikcioglu, Levent H. Can, Harun Evrengul, Serdar Payzin, Hakan Kultursay. Ege University School of Medicine, Cardiology dept., izmir, Turkey
Journal: Journal of the American College of Cardiology (2001)
Advanced age impairs development of collateral vessels to infarct related artery in patients with acute myocardial infarction Toshiya Kurotobi, Hiroshi Sato, Hideyuki Sato, Issei Shiotani, Eiji Hishida, Kunihiro Kingjoe, Daisaku Nakatani, Atsushi Hirayama, Tsunehiko Kuzuya, Kazuhisa Kodama, Masatsugu Hori. Osaka University Graduate School of Medicine, Suita, Japan, Osaka Police Hospital, Osaka, Japan
Journal: Journal of the American College of Cardiology (2001)
Table of Contents
Authors: Tyler Willenbrink, Emily Ruiz, Christine Cornejo, Chrysalyne Schmults, Sarah Arron, Anokhi Jambusaria-Pahlajani, Dirk Elston, Warren Heymann, Kevin Patel, Harrison Lee, Supriya Rastogi, Paras Vakharia, Tammy Hua, Krishan Ba, Vivek Chhiba, Jonathan Singam, Michael Marchetti, Ashley Yu, Japbani Nanda, Philipp Tschandl, Harald Kittler, Ashfaq Marghoob, Allan Halpern, Stephen Dusza, Anne Drph, Axel Christiansen, Anette Brock, Lars Bygum, Peter Rasmussen, Daisuke Utsumi, Masahito Yasuda, Hiroo Amano, Yasushi Suga, Mariko Seishima, Kenzo Takahashi, Michela Lai, Riccardo Pampena, Luigi Cornacchia, Giovanni Pellacani, Ketty Peris, Caterina Longo, Liora Bik, Tobias Sangers, Karin Greveling, Errol Prens, Merete Haedersdal, Martijn Van Doorn, Cory Smith, Divya Srivastava, Rajiv Nijhawan, Daniel Cole, Audrey Fotouhi, Joseph Fakhoury, Steven Daveluy, Kathryn Bentivegna, Madeline Dewane, Sonal Parikh, Hanspaul Makkar, Justin Finch, Lindsey Voller, Ingrid Polcari, Rishabh Mazmudar, Neha Gupta, Laura Xiang, Raghav Tripathi, Jeremy Bordeaux, Jeffrey Scott, Luc Duteil, Catherine Queille-Roussel, Jean-Philippe Lacour, Henri Montaudie, Thierry Passeron, Jungyoon Ohn, Da-Ae Yu, Hyunsun Park, Soyun Cho, Je-Ho Mun, Katherine Thompson, Marina Shuster, Bao Ly, Corina Antonescu, Liliana Florea, Anna Chien, Sewon Kang, Arjun Bashyam, Adrian Cuellar-Barboza, Rima Ghamrawi, Steven Feldman, Danna Moustafa, Jiade Yu, Isabel Nip, Paula Feng, Hao Feng, David Siegel, Jayne Joo, Rachel Cortez, Theresa Furlong, R Isseroff, Qisi Sun, Ivy Ren, Theodore Zaki, Kaitlin Maciejewski, Keith Choate, Bukhtawar Waqas, Victoria Cooley, Shari Lipner, Javier Jimenez, Eran Gwillim, Cory Kosche, Anna Figueiredo, Corrine Rauck, Stephanie Ba, Jennifer Rangel, Dennis Choi, Beatrice West, Mario Lacouture
Journal: Journal of the American Academy of Dermatology (2020)
Exercise-induced piezoelectric stimulation for cartilage regeneration in rabbits
Authors: Yang Liu, Godwin Dzidotor, Thinh T. Le, Tra Vinikoor, Kristin Morgan, Eli J. Curry, Ritopa Das, Aneesah McClinton, Ellen Eisenberg, Lorraine N. Apuzzo, Khanh T. M. Tran, Pooja Prasad, Tyler J. Flanagan, Seok-Woo Lee, Ho-Man Kan, Meysam T. Chorsi, Kevin W. H. Lo, Cato T. Laurencin, Thanh D. Nguyen
Journal: Science Translational Medicine (2022)

More than 32.5 million American adults suffer from osteoarthritis, and current treatments including pain medicines and anti-inflammatory drugs only alleviate symptoms but do not cure the disease. Here, we have demonstrated that a biodegradable piezoelectric poly(L-lactic acid) (PLLA) nanofiber scaffold under applied force or joint load could act as a battery-less electrical stimulator to promote chondrogenesis and cartilage regeneration. The PLLA scaffold under applied force or joint load generated a controllable piezoelectric charge, which promoted extracellular protein adsorption, facilitated cell migration or recruitment, induced endogenous TGF-β via calcium signaling pathway, and improved chondrogenesis and cartilage regeneration both in vitro and in vivo. Rabbits with critical-sized osteochondral defects receiving the piezoelectric scaffold and exercise treatment experienced hyaline-cartilage regeneration and completely healed cartilage with abundant chondrocytes and type II collagen after 1 to 2 months of exercise (2 to 3 months after surgery including 1 month of recovery before exercise), whereas rabbits treated with nonpiezoelectric scaffold and exercise treatment had unfilled defect and limited healing. The approach of combining biodegradable piezoelectric tissue scaffolds with controlled mechanical activation (via physical exercise) may therefore be useful for the treatment of osteoarthritis and is potentially applicable to regenerating other injured tissues.
Joseph Goldberger Fellowship grants for research in clinical nutrition
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Let's not forget the basics
Authors: None The Lancet Microbe
Journal: The Lancet Microbe (2020)

As countries worldwide relax the measures they had put in place to contain the COVID-19 epidemic, on June 21, WHO recorded the largest yet 24-h increase in global cases. Just over a week earlier, China had reported a new outbreak in Beijing, after almost 2 months without local transmissions. These events are stark reminders to countries that believe they have overcome the worse, that the pandemic is not over and now is not a time to be complacent. The possibility of returning to a truly pre-pandemic lifestyle relies on the development and widespread availability of a vaccine or treatment.
Turning gray selenium into a nanoaccelerator of tissue regeneration by PEG modification
Authors: Jieqiong Cao, Yibo Zhang, Peiguang Zhang, Zilei Zhang, Bihui Zhang, Yanxian Feng, Zhixin Li, Yiqi Yang, Qilin Meng, Liu He, Yulin Cai, Zhenyu Wang, Jie Li, Xue Chen, Hongwei Liu, An Hong, Wenjie Zheng, Xiaojia Chen
Journal: Bioactive Materials (2022)

Selenium (Se) is an essential trace element involved in nearly all human physiological processes but suffers from a narrow margin between benefit and toxicity. The nanoform of selenium has been proven shown to be more bioavailable and less toxic, yet significant challenges remain regarding the efficient and feasible synthesis of biologically active nanoselenium. In addition, although nanoselenium has shown a variety of biological activities, more interesting nanoselenium features are expected. In this work, hydrosoluble nanoselenium termed Nano-Se in the zero oxidation state was synthesized between gray Se and PEG. A zebrafish screen was carried out in zebrafish larvae cocultured with Nano-Se. Excitingly, Nano-Se promoted the action of the FGFR, Wnt, and VEGF signaling pathways, which play crucial roles in tissue regeneration. As expected, Nano-Se not only achieved the regeneration of zebrafish tail fins and mouse skin but also promoted the repair of skin in diabetic mice while maintaining a profitable safe profile. In brief, the Nano-Se reported here provided an efficient and feasible method for bioactive nanoselenium synthesis and not only expanded the application of nanoselenium to regenerative medicine but also likely reinvigorated efforts for discovering more peculiarunique biofunctions of nanoselenium in a great variety of human diseases.
THE THERAPY OF CATARRHAL FEVERS
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Liver-directed concurrent chemoradiotherapy versus sorafenib in hepatocellular carcinoma with portal vein tumor thrombus.
Authors: Jina Kim, Hwa Kyung Byun, Tae Hyung Kim, Sun Il Kim, Beom Kyung Kim, Do Young Kim, Jinsil Seong
Journal: Journal of Clinical Oncology (2022)

424 Background: This study aimed to investigate the efficacy of liver-directed concurrent chemoradiotherapy (LD-CCRT) compared with sorafenib in patients with liver-confined locally advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT). Methods: Patients treated with sorafenib and LD-CCRT between 2005 and 2016 were reviewed. Patients with extrahepatic disease and those without PVTT were excluded, leaving 28 and 448 patients in the sorafenib and LD-CCRT groups, respectively. Propensity score matching was performed to balance the differences in clinical features between the two groups. Results: At baseline, the sorafenib group presented higher incidences of unfavorable clinical features, including type 3-4 PVTT (53.6% vs. 30.6%) and bilateral disease extent (64.3% vs. 31.5%), than the LD-CCRT group. A total of 27 patients from the sorafenib group and 52 patients from the LD-CCRT group were matched. At a median follow-up duration of 73 months (range, 11-110 months), the median overall survival (OS) was 4.0 and 8.7 months in the sorafenib and LD-CCRT groups, respectively (p = 0.001). The Cox proportional hazard model showed that LD-CCRT was a significant prognostic factor for OS. One patient from the sorafenib group and seven patients from the LD-CCRT group underwent surgical treatment (liver transplantation or liver resection). Patients who underwent surgical treatment had significantly longer OS than those who did not undergo surgery. Conclusions: LD-CCRT showed superior survival outcomes to sorafenib in HCC patients with PVTT. LD-CCRT could be an efficient means of local tumor control that can enable surgical treatment with a curative intent in selected patients.
Corrections
Authors: Chas. E. Banks
Journal: JAMA (1883)

—We take pleasure in copying the following notes, which will explain themselves: December22, 1883. <h3>Mr. Editor:</h3> —In your issue of December 15, there was a review of the Annual Report of the Supervising Surgeon-General of the Marine-Hospital Service for the year 1883, in which the reviewer has fallen into an error, evidently due to his misapprehension of the system employed in reporting autopsies. On page 685, first column of your journal, he has noted a case, reported on page 229 of the Report, in which he states there was " no diagnosis." For the benefit of those who may fall into the same error, it seems proper to state that there are reported several autopsies of patients dying from the same disease, each of which is serially numbered. He will find that the case to which he alludes is No. 8 of the series of "Diseases of the Heart," the
Immunotherapy for the Neoadjuvant Management of Resectable Intrathoracic Cancers
Authors: Joe Y. Chang, Vivek Verma, Ralph R. Weichselbaum
Journal: JAMA Oncology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Clinical utility of microsatellite instability (MSI-H) identified on liquid biopsy in advanced gastrointestinal cancers (aGI).
Authors: Pashtoon Murtaza Kasi, Samuel J Klempner, Jason S. Starr, Ardaman Shergill, Leslie A. Bucheit, Caroline Weipert, Jiemin Liao, Jing Zhao, Aaron Hardin, Nicole Zhang, Kathryn Lang
Journal: Journal of Clinical Oncology (2022)

56 Background: Identification of MSI-H is clinically meaningful in patients with aGI given the associated approval of multiple immune checkpoint inhibitors. MSI-H has long been assessed via tissue analysis; and insights from plasma-based approaches are limited to small validation studies. We sought to assess prevalence of initial and acquired MSI-H status across aGI and report real-world outcomes of colorectal (CRC) patients who received ICI after MSI-H identification by a commercially available liquid biopsy (LBx) assay. Methods: Genomic results from a well-validated LBx assay (Guardant360) completed as part of usual clinical care between 10/1/2018-9/7/2021 in patients with aGI were queried to assess MSI-H prevalence and identify cases of potential acquired MSI-H. Real-world evidence (RWE) was sourced from the GuardantINFORM database comprised of aggregated payer claims and de-identified records from 11/1/2018-3/31/2021. Patients with plasma-identified MSI-H who started new therapy &lt; 60 days after assay report date were sorted into treatment groups: chemotherapy +/- biologic therapy (“chemo”) or immunotherapy via pembrolizumab or nivolumab (“ICI”). Real-world time to discontinuation (rwTTD) and real-world time to next treatment (rwTTNT) were assessed as proxies for progression free survival. Log-rank tests were used to assess differences in rwTTD, rwTTNT and overall survival. Results: Prevalence of MSI-H was ̃2% across aGI (Table). Five cases were observed to have potential acquired MSI not attributable to tumor shed identified on serial LBx tests. Of 222 MSI-H CRC patients eligible for RWE analysis, 89(40%) started new therapy within 60 days of results: 42(48%) received ICI, 39(44%) received chemo, 8(9%) received other/mixed regimens. Patients who received ICI had significantly longer rwTTD and rwTTNT compared to patients who received chemo [median months to discontinuation = 7.5 (95% CI 3.4-12.3) vs. 2 (95% 1.4-3.3) p&lt;0.001; median months to next treatment = 23.8 (95% 10.6-NA) vs. 4.5 (95% CI 2.9-NA) p=0.006]; no overall survival difference was observed (p=0.559). Conclusions: This LBx assay detected MSI-H at similar frequencies to published tissue cohorts and may identify acquired MSI-H following early lines of therapy. Patients who received ICI following LBx identification of MSI-H achieved responses in line with published data in previously treated aGI. Well-validated LBx is a viable tool to identify initial and acquired MSI-H in aGI and may expand the number of patients who could benefit from ICI therapy, particularly in cases where access to tissue specimens is not feasible. [Table: see text]
Effect of sacubitril/valsartan on investigator‐reported ventricular arrhythmias in <scp>PARADIGM‐HF</scp>
Authors: James P. Curtain, Alice M. Jackson, Li Shen, Pardeep S. Jhund, Kieran F. Docherty, Mark C. Petrie, Davide Castagno, Akshay S. Desai, Luis E. Rohde, Martin P. Lefkowitz, Jean‐Lucien Rouleau, Michael R. Zile, Scott D. Solomon, Karl Swedberg, Milton Packer, John J.V. McMurray
Journal: European Journal of Heart Failure (2021)

Sudden death is a leading cause of mortality in heart failure with reduced ejection fraction (HFrEF). In PARADIGM-HF, sacubitril/valsartan reduced the incidence of sudden death. The purpose of this post hoc study was to analyse the effect of sacubitril/valsartan, compared to enalapril, on the incidence of ventricular arrhythmias.Adverse event reports related to ventricular arrhythmias were examined in PARADIGM-HF. The effect of randomized treatment on two arrhythmia outcomes was analysed: ventricular arrhythmias and the composite of a ventricular arrhythmia, implantable cardioverter defibrillator (ICD) shock or resuscitated cardiac arrest. The risk of death related to a ventricular arrhythmia was examined in time-updated models. The interaction between heart failure aetiology, or baseline ICD/cardiac resynchronization therapy-defibrillator (CRT-D) use, and the effect of sacubitril/valsartan was analysed. Of the 8399 participants, 333 (4.0%) reported a ventricular arrhythmia and 372 (4.4%) the composite arrhythmia outcome. Ventricular arrhythmias were associated with higher mortality. Compared with enalapril, sacubitril/valsartan reduced the risk of a ventricular arrhythmia (hazard ratio [HR] 0.76, 95% confidence interval [CI] 0.62-0.95; p = 0.015) and the composite arrhythmia outcome (HR 0.79, 95% CI 0.65-0.97; p = 0.025). The treatment effect was maintained after adjustment and accounting for the competing risk of death. Baseline ICD/CRT-D use did not modify the effect of sacubitril/valsartan, but aetiology did: HR in patients with an ischaemic aetiology 0.93 (95% CI 0.71-1.21) versus 0.53 (95% CI 0.37-0.78) in those without an ischaemic aetiology (p for interaction = 0.020).Sacubitril/valsartan reduced the incidence of investigator-reported ventricular arrhythmias in patients with HFrEF. This effect may have been greater in patients with a non-ischaemic aetiology.
Abstract 314: BRaf Plays a Major Role in Gene Expression in Cardiomyocytes in Mouse Hearts <i>in vivo</i>
Authors: Michelle A Hardyman, Stephen J Fuller, Daniel N Meijles, Kerry A Rostron, Sam J Leonard, Peter H Sugden, Angela Clerk
Journal: Circulation Research (2017)

Introduction: Raf kinases lie upstream of ERK1/2 with BRaf being the most highly expressed and having the highest basal activity. V600E BRaf mutations constitutively activate ERK1/2 and are common in cancer. The role of BRaf in the adult heart is yet to be established. ERK1/2 regulate cardiomyocyte gene expression, promoting cardiac hypertrophy and cardioprotection, but effects of ERK1/2 may depend on signal strength. Hypothesis: Our hypotheses are that BRaf is critical in regulating ERK1/2 signaling in cardiomyocytes and, whilst moderate ERK1/2 activity is beneficial, excessive ERK1/2 activity is detrimental to the heart. Methods: We generated heterozygote mice for tamoxifen- (Tam-) inducible cardiomyocyte-specific knockin of V600E in the endogenous BRaf gene. Mice (12 wks) received 2 injections of Tam or vehicle on consecutive days (n=4-10 per group). Kinase activities and mRNA expression were assessed by immunoblotting and qPCR. Echocardiography was performed (Vevo2100). M-mode images (short axis view) were analyzed; data for each mouse were normalized to the mean of 2 baseline controls. Results: V600E knockin did not affect overall BRaf or cRaf levels in mouse hearts, but significantly increased ERK1/2 activities within 48 h (1.51±0.05 fold). Concurrently, mRNAs for hypertrophic gene markers including BNP and immediate early genes (IEGs) increased signficantly. At 72 h, expression of BNP, Fosl1, Myc, Ereg and CTGF increased further, other IEGs (Jun, Fos, Egr1, Atf3) declined, and ANF was upregulated. In contrast, expression of α and β myosin heavy chain mRNAs was substantially downregulated (0.46/0.41±0.05 relative to controls). Within 72 h, left ventricular (LV) mass and diastolic LV wall thickness had increased (1.23±0.05 relative to controls), but cardiac function was severely compromised with significant decreases in ejection fraction and cardiac output (0.53/0.68±0.09 relative to controls) associated with increased LV internal diameters and cardiac volumes. Conclusions: Endogenous cardiomyocyte BRaf is sufficient to activate ERK1/2 in mouse hearts and induce cardiac hypertrophy associated with dynamic temporal changes in gene expression. However, excessive activation of ERK1/2 in isolation is detrimental to cardiac function.
Prevalence of ligament of marshall potentials recording in patients with paroxysmal atrial fibrillation Demosthenes Katritsis, Eleftherios Giazitzoglou, Socrates Korovesis, John Parissis, Pericles Kalivas, John Ioannidis, George Sarris, A John Camm. ATHENS EUROCLINIC, ATHENS, GREECE, Greece, UNIVERSITY OF IOANNINA, IOANNINA, Greece
Journal: Journal of the American College of Cardiology (2001)